Oxidation increases mucin polymer cross-links to stiffen airway mucus gels

Science Translational Medicine

Volumn 7, Issue 276, 2015, Pages

  Yuan, Shaopeng ^a   Hollinger, Martin ^b   Lachowicz Scroggins, Marrah E ^a   Kerr, Sheena C ^a   Dunican, Eleanor M ^a   Daniel, Brian M ^a   Ghosh, Sudakshina ^c   Erzurum, Serpel C ^c   Willard, Belinda ^c   Hazen, Stanley L ^c   Huang, Xiaozhu ^d   Carrington, Stephen D ^b   Oscarson, Stefan ^b   Fahy, John V ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c LERNER RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EOSINOPHIL PEROXIDASE; MUCIN; MUCOLYTIC AGENT; ACETYLCYSTEINE; CROSS LINKING REAGENT; DISULFIDE; DNA; EXPECTORANT AGENT; GALACTOSE; GEL; POLYMER; REDUCING AGENT; THIOL DERIVATIVE;

AIRWAY; ANTIOXIDANT ACTIVITY; ARTICLE; BRONCHUS MUCUS; CARBOHYDRATE SYNTHESIS; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYSTIC FIBROSIS; DISULFIDE BOND; DRUG EFFICACY; ELASTICITY; EOSINOPHILIA; FLOW KINETICS; HUMAN; HUMAN TISSUE; MASS SPECTROMETRY; MOLECULAR DYNAMICS; MUCOLYSIS; NEUTROPHILIA; OXIDATION; OXIDATION REDUCTION POTENTIAL; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN CROSS LINKING; PROTEIN PROCESSING; PROTEIN TARGETING; VISCOSITY; ANIMAL; BIOMECHANICS; C57BL MOUSE; CHEMISTRY; DRUG EFFECTS; GEL; LUNG; METABOLISM; MUCUS; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SPUTUM;

ACETYLCYSTEINE; ANIMALS; BIOMECHANICAL PHENOMENA; CROSS-LINKING REAGENTS; CYSTIC FIBROSIS; DISULFIDES; DNA; ELASTICITY; EXPECTORANTS; GALACTOSE; GELS; HUMANS; LUNG; MICE, INBRED C57BL; MUCINS; MUCUS; OXIDATION-REDUCTION; OXIDATIVE STRESS; POLYMERS; REDUCING AGENTS; SPUTUM; SULFHYDRYL COMPOUNDS;

EID: 84923870560     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3010525     Document Type: Article

References (42)

1. D. J. Thornton, K. Rousseau, M. A. McGuckin, Structure and function of the polymeric mucins in airways mucus. Annu. Rev. Physiol. 70, 459-486 (2008).
2. M. G. Roy, A. Livraghi-Butrico, A. A. Fletcher, M. M. McElwee, S. E. Evans, R. M. Boerner, S. N. Alexander, L. K. Bellinghausen, A. S. Song, Y. M. Petrova, M. J. Tuvim, R. Adachi, I. Romo, A. S. Bordt, M. G. Bowden, J. H. Sisson, P. G. Woodruff, D. J. Thornton, K. Rousseau, M. M. De laGarza, S. J. Moghaddam, H. Karmouty-Quintana, M. R. Blackburn, S. M. Drouin, C. W. Davis, K. A. Terrell, B. R. Grubb, W. K. O' Neal, S. C. Flores, A. Cota-Gomez, C. A. Lozupone, J. M. Donnelly, A. M. Watson, C. E. Hennessy, R. C. Keith, I. V. Yang, L. Barthel, P. M. Henson, W. J. Janssen, D. A. Schwartz, R. C. Boucher, B. F. Dickey, C. M. Evans, Muc5b is required for airway defence. Nature 505, 412-416 (2014).
3. A. L. Innes, S. D. Carrington, D. J. Thornton, S. Kirkham, K. Rousseau, R. H. Dougherty, W. W. Raymond, G. H. Caughey, S. J. Muller, J. V. Fahy, Ex vivo sputum analysis reveals impairment of protease-dependent mucus degradation by plasma proteins in acute asthma. Am. J. Respir. Crit. Care Med. 180, 203-210 (2009).
4. J. V. Fahy, B. F. Dickey, Airwaymucus function and dysfunction. N. Engl. J. Med. 363, 2233-2247 (2010).
5. M. King, Physiology of mucus clearance. Paediatr. Respir. Rev. 7 (Suppl. 1), S212-S214 (2006).
6. D. Ambort, S. van der Post, M. E. Johansson, J. Mackenzie, E. Thomsson, U. Krengel, G. C. Hansson, Function of the CysD domain of the gel-forming MUC2 mucin. Biochem. J. 436, 61-70 (2011).
7. M. C. Rose, J. A. Voynow, Respiratory tract mucin genes and mucin glycoproteins in health and disease. Physiol. Rev. 86, 245-278 (2006).
8. A. M. Cantin, S. L. North, R. C. Hubbard, R. G. Crystal, Normal alveolar epithelial lining fluid contains high levels of glutathione. J. Appl. Physiol. 63, 152-157 (1987).
9. C. E. Cross, A. van der Vliet, C. A. O'Neill, S. Louie, B. Halliwell, Oxidants, antioxidants, and respiratory tract lining fluids. Environ. Health Perspect. 102 (Suppl. 10), 185-191 (1994).
10. S. R. Hays, J. V. Fahy, Characterizing mucous cell remodeling in cystic fibrosis: Relationship to neutrophils. Am. J. Respir. Crit. Care Med. 174, 1018-1024 (2006).
11. A. van der Vliet, C. E. Cross, Phagocyte oxidants and nitric oxide in cystic fibrosis: New therapeutic targets? Curr. Opin. Pulm. Med. 6, 533-539 (2000).
12. A. van der Vliet, M. N. Nguyen, M. K. Shigenaga, J. P. Eiserich, G. P. Marelich, C. E. Cross, Myeloperoxidase and protein oxidation in cystic fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 279, L537-L546 (2000).
13. H. Nielsen, S. Hvidt, C. A. Sheils, P. A. Janmey, Elastic contributions dominate the viscoelastic properties of sputum from cystic fibrosis patients. Biophys. Chem. 112, 193-200 (2004).
14. M. L. Brennan, M. M. Anderson, D. M. Shih, X. D. Qu, X. Wang, A. C. Mehta, L. L. Lim, W. Shi, S. L. Hazen, J. S. Jacob, J. R. Crowley, J. W. Heinecke, A. J. Lusis, Increased atherosclerosis in myeloperoxidase-deficient mice. J. Clin. Invest. 107, 419-430 (2001).
15. M. L. Brennan, W. Wu, X. Fu, Z. Shen, W. Song, H. Frost, C. Vadseth, L. Narine, E. Lenkiewicz, M. T. Borchers, A. J. Lusis, J. J. Lee, N. A. Lee, H. M. Abu-Soud, H. Ischiropoulos, S. L. Hazen, A tale of two controversies: Defining both the role of peroxidases in nitrotyrosine formation in vivo using eosinophil peroxidase and myeloperoxidase-deficient mice, and the nature of peroxidase-generated reactive nitrogen species. J. Biol. Chem. 277, 17415-17427 (2002).
16. J. S. Jacob, D. P. Cistola, F. F. Hsu, S. Muzaffar, D. M. Mueller, S. L. Hazen, J. W. Heinecke, Human phagocytes employ the myeloperoxidase-hydrogen peroxide system to synthesize dityrosine, trityrosine, pulcherosine, and isodityrosine by a tyrosyl radical-dependent pathway. J. Biol. Chem. 271, 19950-19956 (1996).
17. S. B. Ho, K. Takamura, R. Anway, L. L. Shekels, N. W. Toribara, H. Ota, The adherent gastric mucous layer is composed of alternating layers of MUC5AC and MUC6 mucin proteins. Dig. Dis. Sci. 49, 1598-1606 (2004).
18. R. Sturmer, S. Muller, F.G. Hanisch, W. Hoffmann, Porcine gastric TFF2 is amucus constituent and differs from pancreatic TFF2. Cell. Physiol. Biochem. 33, 895-904 (2014).
19. S. Liu, L. Zhou, L. Chen, S. G. Dastidar, C. Verma, J. Li, D. Tan, R. Beuerman, Effect of structural parameters of peptides on dimer formation and highly oxidized side products in the oxidation of thiols of linear analogues of human β-defensin 3 by DMSO. J. Pept. Sci. 15, 95-106 (2009).
20. J. T. Snow, J. W. Finley, M. Friedman, Oxidation of sulfhydryl groups to disulfides by sulfoxides. Biochem. Biophys. Res. Commun. 64, 441-447 (1975).
21. J. Tam, C. Wu, W. Liu, J. Zhang, Disulfide bind formation in peptides by dimethyl sulfoxide. Scope and applications. J. Am. Chem. Soc. 113, 6657-6662 (1991).
22. L. Edmark, U. Auner, M. Enlund, E. Ostberg, G. Hedenstierna, Oxygen concentration and characteristics of progressive atelectasis formation during anaesthesia. Acta Anaesthesiol. Scand. 55, 75-81 (2011).
23. 2much of a good thing? Crit. Care 15, 305 (2011).
24. A. Reber, G. Engberg, G. Wegenius, G. Hedenstierna, Lung aeration. The effect of preoxygenation and hyperoxygenation during total intravenous anaesthesia. Anaesthesia 51, 733-737 (1996).
25. R. Balsamo, L. Lanata, C. G. Egan, Mucoactive drugs. Eur. Respir. Rev. 19, 127-133 (2010).
26. A. Yuta, J. N. Baraniuk, Therapeutic approaches to mucus hypersecretion. Curr. Allergy Asthma Rep. 5, 243-251 (2005).
27. M. J. Telko, A. J. Hickey, Dry powder inhaler formulation. Respir. Care 50, 1209-1227 (2005).
28. M. J. Hoegger, A. J. Fischer, J. D. McMenimen, L. S. Ostedgaard, A. J. Tucker, M. A. Awadalla, T. O. Moninger, A. S. Michalski, E. A. Hoffman, J. Zabner, D. A. Stoltz, M. J. Welsh, Cystic fibrosis. Impaired mucus detachment disrupts mucociliary transport in a piglet model of cystic fibrosis. Science 345, 818-822 (2014).
29. S. A. Comhair, S. C. Erzurum, Redox control of asthma: Molecular mechanisms and therapeutic opportunities. Antioxid. Redox Signal. 12, 93-124 (2010).
30. J. Ciencewicki, S. Trivedi, S. R. Kleeberger, Oxidants and the pathogenesis of lung diseases. J. Allergy Clin. Immunol. 122, 456-468; quiz 469-470 (2008).
31. E. M. Drost, K. M. Skwarski, J. Sauleda, N. Soler, J. Roca, A. Agusti, W. MacNee, Oxidative stress and airway inflammation in severe exacerbations of COPD. Thorax 60, 293-300 (2005).
32. W. MacNee, Oxidants/antioxidants and COPD. Chest 117, 303S-317S (2000).
33. M. Wilkinson, K. Sugumar, S. J. Milan, A. Hart, A. Crockett, I. Crossingham, Mucolytics for bronchiectasis. Cochrane Database Syst. Rev. 5, CD001289 (2014).
34. J. Tam, E. F. Nash, F. Ratjen, E. Tullis, A. Stephenson, Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis. Cochrane Database Syst. Rev. 7, CD007168 (2013).
35. Y. Shen, W. Cai, S. Lei, Z. Zhang, Effect of high/low dose N-acetylcysteine on chronic obstructive pulmonary disease: A systematic review and meta-analysis. COPD 11, 351-358 (2014).
36. C. Conrad, J. Lymp, V. Thompson, C. Dunn, Z. Davies, B. Chatfield, D. Nichols, J. Clancy, R. Vender, M. E. Egan, L. Quittell, P. Michelson, V. Antony, J. Spahr, R. C. Rubenstein, R. B. Moss, L. A. Herzenberg, C. H. Goss, R. Tirouvanziam, Long-term treatment with oral N-acetylcysteine: Affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trial. J. Cyst. Fibros. 10.1016/j.jcf.2014.08.008 (2014).
37. I. A. Cotgreave, A. Eklund, K. Larsson, P. W. Moldeus, No penetration of orally administered N-acetylcysteine into bronchoalveolar lavage fluid. Eur. J. Respir. Dis. 70, 73-77 (1987).
38. K. R. Gibson, I. L. Neilson, F. Barrett, T. J. Winterburn, S. Sharma, S. M. MacRury, I. L. Megson, Evaluation of the antioxidant properties of N-acetylcysteine in human platelets: Prerequisite for bioconversion to glutathione for antioxidant and antiplatelet activity. J. Cardiovasc. Pharmacol. 54, 319-326 (2009).
39. P. G. Woodruff, M. Wolff, J. M. Hohlfeld, N. Krug, M. T. Dransfield, E. R. Sutherland, G. J. Criner, V. Kim, A. Prasse, M. C. Nivens, K. Tetzlaff, R. Heilker, J. V. Fahy, Safety and efficacy of an inhaled epidermal growth factor receptor inhibitor (BIBW 2948 BS) in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 181, 438-445 (2010).
40. N. H. Gershman, H. H. Wong, J. T. Liu, M. J. Mahlmeister, J. V. Fahy, Comparison of two methods of collecting induced sputum in asthmatic subjects. Eur. Respir. J. 9, 2448-2453 (1996).
41. A. E. Feldstein, R. Lopez, T. A. Tamimi, L. Yerian, Y. M. Chung, M. Berk, R. Zhang, T. M. McIntyre, S. L. Hazen, Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J. Lipid Res. 51, 3046-3054 (2010).
42. M. J. Citardi, W. Song, P. S. Batra, D. C. Lanza, S. L. Hazen, Characterization of oxidative pathways in chronic rhinosinusitis and sinonasal polyposis. Am. J. Rhinol. 20, 353-359 (2006).